maklogo
Market Research Report

Global Medical Radioactive Isotopes Market Insights, Size, and Forecast By Isotope Type (Technetium-99m, Iodine-131, Cobalt-60, Iridium-192), By Source (Natural, Artificial), By End Use (Hospitals, Diagnostic Laboratories, Research Institutes, Cancer Treatment Centers), By Application (Therapeutic, Diagnostic Imaging, Research), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:87347
Published Date:Jan 2026
No. of Pages:211
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Medical Radioactive Isotopes Market is projected to grow from USD 6.8 Billion in 2025 to USD 13.5 Billion by 2035, reflecting a compound annual growth rate of 7.6% from 2026 through 2035. This market encompasses the production, distribution, and utilization of radioactive isotopes specifically engineered for medical applications, primarily in diagnostics and therapy. Medical radioactive isotopes, often referred to as radioisotopes or radionuclides, are unstable atoms that emit radiation as they decay, allowing for their detection and use in medical imaging or targeted treatment. The increasing prevalence of chronic diseases, particularly cancer and cardiovascular disorders, is a primary driver fueling market expansion. The growing demand for early and accurate disease diagnosis, coupled with advancements in nuclear medicine imaging techniques like PET and SPECT, significantly contributes to market growth. Additionally, the rising elderly population, a demographic more susceptible to various health conditions requiring advanced diagnostic and therapeutic interventions, further propels the adoption of these isotopes. However, the market faces significant restraints, including the complex regulatory landscape surrounding the production and use of radioactive materials, high capital investment required for cyclotron facilities, and concerns regarding radiation exposure risks for both patients and healthcare professionals. Supply chain vulnerabilities, often due to the limited number of production facilities and the short half-life of many isotopes, also pose a considerable challenge.

Global Medical Radioactive Isotopes Market Value (USD Billion) Analysis, 2025-2035

maklogo
7.6%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Despite these hurdles, substantial opportunities exist within the market. The development of novel radioisotopes with improved imaging capabilities and therapeutic efficacy presents a significant growth avenue. Furthermore, the increasing adoption of personalized medicine approaches, where tailored diagnostic and therapeutic strategies are crucial, is expected to drive demand for highly specific and targeted radioisotopes. The expansion of healthcare infrastructure in emerging economies and the rising awareness about the benefits of nuclear medicine procedures are also creating new market avenues. North America currently dominates the global market, driven by its advanced healthcare infrastructure, high adoption rate of nuclear medicine procedures, substantial research and development investments, and the presence of key market players. The region benefits from a well-established regulatory framework and strong reimbursement policies that support the use of radioactive isotopes in medical settings.

Asia Pacific is anticipated to be the fastest growing region in the medical radioactive isotopes market. This rapid growth is attributed to several factors, including the increasing incidence of chronic diseases, a burgeoning patient population, improving healthcare expenditure, and the modernization of healthcare facilities across the region. Furthermore, government initiatives aimed at enhancing nuclear medicine capabilities and increasing awareness about advanced diagnostic techniques are contributing to the robust expansion of the market in Asia Pacific. Key players in this competitive landscape include Cisbio International, Thermo Fisher Scientific, Belgian Nuclear Research Centre, Cardinal Health, Lantheus Medical Imaging, Elekta, Tractebel, Nuclear Medicine Partners, NorthStar Medical Radioisotopes, and General Electric. These companies are actively engaged in strategic initiatives such as mergers and acquisitions, collaborations, new product development, and geographic expansion to strengthen their market position and address the evolving demands of the healthcare sector. Their strategies often focus on enhancing production capabilities, improving supply chain efficiency, and investing in research and development to introduce innovative radioisotopes with superior performance and safety profiles.

Quick Stats

  • Market Size (2025):

    USD 6.8 Billion

  • Projected Market Size (2035):

    USD 13.5 Billion

  • Leading Segment:

    Diagnostic Imaging (65.4% Share)

  • Dominant Region (2025):

    North America (41.2% Share)

  • CAGR (2026-2035):

    7.6%

Global Medical Radioactive Isotopes Market Emerging Trends and Insights

Theranostics Resurgence Radioisotope Innovation

Theranostics, the fusion of diagnostics and therapy, is experiencing a significant resurgence, largely driven by groundbreaking radioisotope innovation. This trend is characterized by the development of novel radionuclides and sophisticated radiolabeling techniques that enable more precise disease detection and targeted treatment. New generation radioisotopes offer improved half lives, higher specific activities, and diverse emission profiles, allowing for superior imaging quality and more effective therapeutic delivery, particularly in oncology and neurology. This innovation facilitates the creation of highly specific radiopharmaceuticals that can accurately locate and treat diseased cells while minimizing damage to healthy tissues. The ability to image a tumor or a pathological process and then treat it with the same molecular entity, tailored to individual patient needs, is revolutionizing personalized medicine.

AI Powered Isotope Production Optimization

AI Powered Isotope Production Optimization is a transformative trend in the global medical radioactive isotopes market. It leverages artificial intelligence to enhance the efficiency and reliability of isotope manufacturing processes. AI algorithms analyze vast datasets from reactors and particle accelerators, predicting optimal irradiation times, target material composition, and processing parameters. This leads to increased yields of critical medical isotopes like Molybdenum 99 and Lutetium 177, while simultaneously reducing waste and energy consumption. The technology also allows for better predictive maintenance of production facilities, minimizing downtime and ensuring a more consistent supply chain. Furthermore, AI can model complex nuclear reactions, enabling the development of novel production methods for new therapeutic and diagnostic isotopes, ultimately improving patient access to life saving radiopharmaceuticals worldwide.

Sustainable Supply Chain Enhanced Reliability

The global medical radioactive isotopes market is witnessing a significant trend: Sustainable Supply Chain Enhanced Reliability. This addresses historical fragilities like reactor shutdowns and complex logistics hindering consistent isotope availability. Instead of relying on a few aging reactors, the industry is diversifying production sources globally, including new reactor builds and accelerator based technologies. Efforts focus on optimizing transportation routes, investing in more robust shipping containers, and developing redundant distribution networks. Enhanced inventory management systems and predictive analytics further minimize disruptions. Collaboration among producers, distributors, and healthcare providers through formalized agreements and shared data platforms is strengthening the entire supply chain. This holistic approach aims to create a more resilient, transparent, and responsive system, ensuring a dependable supply of critical isotopes for patient diagnostics and treatment worldwide, ultimately improving healthcare outcomes.

What are the Key Drivers Shaping the Global Medical Radioactive Isotopes Market

Rising Incidence of Chronic Diseases Fueling Demand for Nuclear Medicine

The increasing prevalence of chronic diseases globally is a significant driver for the nuclear medicine market. Conditions such as various cancers, cardiovascular diseases, and neurological disorders like Alzheimer’s are on the rise. Nuclear medicine techniques provide crucial diagnostic information and therapeutic options for these illnesses. For instance, PET scans and SPECT scans, utilizing radioactive isotopes, help detect early stages of cancer, assess heart function, and diagnose neurodegenerative conditions. As the population ages and lifestyles contribute to chronic disease development, the demand for precise and effective diagnostic tools and targeted therapies intensifies. Radioactive isotopes are indispensable in these applications, facilitating early diagnosis, monitoring disease progression, and guiding personalized treatments, thereby directly fueling the growth of the medical radioactive isotopes market.

Technological Advancements in Isotope Production and Imaging Modalities

Technological advancements are profoundly shaping the medical radioactive isotopes market. Innovations in isotope production methods, such as enhanced reactor utilization and accelerator technologies like cyclotrons and linear accelerators, are improving yield, purity, and enabling the creation of novel isotopes with more favorable properties. Simultaneously, breakthroughs in imaging modalities, including Positron Emission Tomography PET and Single Photon Emission Computed Tomography SPECT scanners, are leading to higher resolution, sensitivity, and faster scan times. These advancements translate to more precise diagnoses, better disease staging, and improved therapeutic outcomes for patients. Furthermore, research into targeted radiopharmaceuticals and theranostic agents is expanding the applications of these isotopes, driving demand across a wider range of medical conditions and fostering market expansion.

Expanding Healthcare Infrastructure and Investment in Diagnostic Imaging

Growing global investment in healthcare infrastructure directly fuels the demand for medical radioactive isotopes. As more hospitals and diagnostic centers are built or modernized, particularly in emerging economies, the need for advanced imaging capabilities increases. This expansion includes the acquisition of new SPECT and PET scanners, which are reliant on a steady supply of isotopes like Technetium 99m and Fluorine 18. Governments and private entities are allocating substantial funds to improve patient care, early disease detection, and treatment monitoring. This continuous infrastructure development broadens access to nuclear medicine procedures, consequently driving the consumption of radioactive isotopes worldwide. Improved healthcare access directly correlates with higher utilization of these crucial diagnostic tools.

Global Medical Radioactive Isotopes Market Restraints

Supply Chain Vulnerability & Geopolitical Instability

The global medical radioactive isotopes market faces significant restraint from supply chain vulnerability and geopolitical instability. Production is highly concentrated with a few key reactors and processing facilities, making the market susceptible to disruptions from unexpected shutdowns, maintenance issues, or natural disasters. Furthermore, the long half life of certain isotopes necessitates international transport, exposing the supply chain to geopolitical tensions, trade disputes, or border closures. Any interruption in this delicate global network can lead to widespread shortages, delaying critical diagnostic procedures and treatments for millions of patients worldwide. Reliance on a limited number of suppliers and the complex logistical requirements exacerbate this inherent fragility, making the market highly sensitive to global events and political climates.

Regulatory Hurdles & High Production Costs

Regulatory hurdles and high production costs significantly restrict the global medical radioactive isotopes market. Strict licensing requirements from bodies like the FDA and EMA for isotope production facilities and the transportation of radioactive materials create substantial delays and financial burdens. These regulations mandate rigorous safety protocols, extensive documentation, and expensive quality control measures, driving up operational expenses. Furthermore, the specialized nature of nuclear reactors required for isotope generation, coupled with the complex and hazardous handling procedures, contributes to high capital expenditure and ongoing operational costs. The short half-lives of many isotopes necessitate efficient and compliant delivery systems, further complicating logistics and adding to costs. These factors combined limit new market entrants and overall supply capacity.

Global Medical Radioactive Isotopes Market Opportunities

Securing Global Supply Through Advanced Isotope Production & Diversification

The opportunity to secure global medical radioactive isotope supply is paramount given existing vulnerabilities and burgeoning demand. Current reliance on a limited number of aging reactors poses significant risks of supply disruptions, impacting patient care worldwide. Advanced isotope production presents a chance to innovate, moving beyond traditional methods to embrace newer technologies like accelerator based production, small modular reactors, or novel processing techniques. This not only enhances efficiency and scalability but also diversifies the production landscape. Diversification involves establishing multiple manufacturing pathways and geographic locations for isotopes, reducing dependence on any single source. This strategic shift mitigates geopolitical risks and operational failures. For instance, the rapidly growing demand in regions like Asia Pacific underscores the urgent need for a robust, resilient, and distributed supply chain. By investing in advanced production and fostering diversification, the industry can ensure consistent, reliable access to critical isotopes for diagnostics and therapies, improving global health outcomes and stabilizing the market against future shocks.

Accelerating Theranostic Radiopharmaceutical Development and Clinical Adoption

The opportunity to accelerate theranostic radiopharmaceutical development and clinical adoption represents a pivotal shift in precision medicine. Theranostics, combining diagnostic imaging with targeted radionuclide therapy, offers unprecedented accuracy in disease management, particularly for oncology. By integrating these capabilities, healthcare providers can tailor treatments more effectively, leading to improved patient outcomes and reduced side effects.

This accelerated progress fuels substantial demand for novel medical radioactive isotopes. Investors and innovators can capitalize by streamlining research pathways, enhancing manufacturing capacities, and facilitating regulatory approvals for these advanced agents. The rapid expansion of healthcare infrastructure and increasing awareness of advanced therapies in regions like Asia Pacific creates a fertile ground for early and widespread clinical integration. Focusing on efficient production, distribution networks, and education will unlock significant value, positioning companies at the forefront of a transformative era in nuclear medicine, driving market growth and patient benefit globally.

Global Medical Radioactive Isotopes Market Segmentation Analysis

Key Market Segments

By Application

  • •Therapeutic
  • •Diagnostic Imaging
  • •Research

By Isotope Type

  • •Technetium-99m
  • •Iodine-131
  • •Cobalt-60
  • •Iridium-192

By End Use

  • •Hospitals
  • •Diagnostic Laboratories
  • •Research Institutes
  • •Cancer Treatment Centers

By Source

  • •Natural
  • •Artificial

Segment Share By Application

Share, By Application, 2025 (%)

  • Diagnostic Imaging
  • Therapeutic
  • Research
maklogo
$6.8BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is By Application Diagnostic Imaging dominating the Global Medical Radioactive Isotopes Market?

Diagnostic Imaging leads the market with a significant share due to its indispensable role in early disease detection and accurate diagnosis. Isotopes like Technetium-99m are extensively used in procedures such as SPECT scans for cardiac imaging, bone scans, and neurological studies. The increasing prevalence of chronic diseases, coupled with advancements in imaging technology that offer non-invasive and precise diagnostic capabilities, drives substantial demand from hospitals and diagnostic laboratories worldwide. This segment provides critical insights for patient management and treatment planning, solidifying its dominant position.

How do specific isotope types shape the market's dynamics?

Technetium-99m is the cornerstone of the medical radioactive isotopes market, predominantly supporting the Diagnostic Imaging segment. Its optimal half-life and gamma ray emission are perfectly suited for various diagnostic procedures. Beyond diagnosis, isotopes like Iodine-131 and Cobalt-60 are crucial for therapeutic applications, particularly in cancer treatment centers for thyroid cancer therapy and radiation therapy respectively. The diverse properties of these isotopes dictate their specific medical applications, creating distinct market niches within both diagnostic and therapeutic areas, and influencing demand across different end-use sectors.

Which end-use segments are key beneficiaries of medical radioactive isotopes?

Hospitals and diagnostic laboratories are primary end-users, extensively utilizing isotopes for their diagnostic imaging departments and nuclear medicine units. These facilities leverage isotopes like Technetium-99m for a broad spectrum of patient diagnostics. Cancer treatment centers form another vital end-use segment, where therapeutic isotopes such as Iodine-131 and Cobalt-60 are critical for targeted radiotherapy and palliation. Research institutes also represent a significant, albeit smaller, segment, driving innovation in isotope development and new clinical applications, thereby contributing to the market's continuous evolution.

Global Medical Radioactive Isotopes Market Regulatory and Policy Environment Analysis

The global medical radioactive isotopes market operates under a highly stringent and fragmented regulatory framework essential for safety and efficacy. International Atomic Energy Agency IAEA standards provide the foundational principles for nuclear safety security and safeguards influencing national legislation worldwide. Regulatory bodies such as the US Food and Drug Administration FDA European Medicines Agency EMA and others implement rigorous processes for radiopharmaceutical approval demanding extensive clinical trials and marketing authorization. Manufacturers must comply with strict Good Manufacturing Practices GMP ensuring product quality and batch consistency. The transportation of radioactive materials is governed by complex regulations from the IAEA International Civil Aviation Organization ICAO and International Maritime Dangerous Goods IMDG Code mandating specialized packaging labeling and handling protocols. Furthermore hospitals and clinics require specific licenses for possessing and administering isotopes adhering to strict radiation protection protocols and waste disposal guidelines. Supply chain security and traceability are also critical concerns necessitating robust oversight.

Which Emerging Technologies Are Driving New Trends in the Market?

Innovations are rapidly transforming the global medical radioactive isotopes market. Emerging production methods are diversifying supply beyond traditional reactors, with accelerator based cyclotrons increasingly producing Technetium 99m and novel isotopes like Gallium 68 and Copper 67, enhancing security and localized availability. This shift supports the rise of next generation theranostics, where diagnostic and therapeutic capabilities are combined.

New therapeutic radioisotopes, especially alpha emitters like Actinium 225 and Lutetium 177, are revolutionizing targeted cancer therapies, offering more precise treatments with reduced systemic toxicity. Advanced imaging technologies, including high resolution PET CT and SPECT CT, are continually improving diagnostic accuracy. Artificial intelligence integration further refines image analysis and treatment planning. Additionally, advancements in radiopharmaceutical development focus on highly specific targeting mechanisms, leveraging biomolecules to deliver isotopes directly to disease sites, promising more effective and personalized patient care across various medical conditions.

Global Medical Radioactive Isotopes Market Regional Analysis

Global Medical Radioactive Isotopes Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
41.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 41.2% share

North America dominates the Global Medical Radioactive Isotopes Market with a substantial 41.2% market share. This dominance is primarily driven by a robust healthcare infrastructure and high adoption rates of nuclear medicine procedures across the United States and Canada. Advanced research and development capabilities, coupled with significant investments in medical imaging technologies, contribute to the region's strong position. The presence of key market players and a well-established regulatory framework further solidify North America's leadership. High awareness among healthcare professionals regarding the benefits of radiopharmaceuticals for diagnosis and treatment also plays a crucial role in maintaining this dominant market presence.

Fastest Growing Region

Asia Pacific · 9.2% CAGR

The Asia Pacific region is poised for significant expansion in the global medical radioactive isotopes market, projected to be the fastest growing region with a robust Compound Annual Growth Rate of 9.2% from 2026 to 2035. This accelerated growth is primarily fueled by increasing healthcare expenditure and a rapidly aging population across several APAC countries. Improved access to advanced medical imaging techniques and radiotherapy in emerging economies is also a key driver. Furthermore rising awareness about early disease diagnosis and the expanding network of diagnostic centers and hospitals capable of utilizing these isotopes contribute substantially to this upward trend. Technological advancements in isotope production and distribution are also playing a crucial role.

Impact of Geopolitical and Macroeconomic Factors

Geopolitically, the medical radioactive isotopes market is highly sensitive to geopolitical tensions and trade disputes affecting uranium enrichment and reactor operations, particularly impacting supply from Russia and Kazakhstan. Nuclear nonproliferation policies impose stringent export controls and licensing requirements, creating significant barriers to entry and expansion for new suppliers and contributing to supply chain fragility. Regulatory landscapes vary widely across nations, with some countries like the US and those in Europe having more rigorous approval processes for new isotopes and production methods, potentially delaying market entry and innovation.

Macroeconomically, the market faces inflationary pressures on raw materials, energy, and logistics, driving up production costs. Exchange rate fluctuations significantly impact the profitability of international suppliers and purchasers, given the global nature of production and consumption. Investment in new reactor technology or alternative production methods like cyclotrons is capital intensive, requiring long term financial commitments. Healthcare budgets and reimbursement policies for nuclear medicine procedures influence demand, with economic downturns potentially reducing patient access or slowing adoption of new radiopharmaceuticals.

Recent Developments

  • March 2025

    NorthStar Medical Radioisotopes announced a strategic partnership with Cardinal Health to expand the distribution network for its non-uranium-based Mo-99. This collaboration aims to ensure a more stable and reliable supply of medical isotopes to hospitals and radiopharmacies across North America, addressing historical supply chain vulnerabilities.

  • September 2024

    Lantheus Medical Imaging launched a new diagnostic imaging agent, utilizing an innovative radioisotope for prostate cancer detection. This product, developed after successful Phase 3 trials, offers improved sensitivity and specificity compared to existing methods, potentially leading to earlier and more accurate diagnoses.

  • June 2025

    Thermo Fisher Scientific acquired a specialized radiopharmaceutical manufacturing facility from a European biotech company. This acquisition significantly boosts Thermo Fisher's production capacity for therapeutic radioisotopes, aligning with their strategy to expand their footprint in the burgeoning radioligand therapy market.

  • November 2024

    General Electric Healthcare initiated a new research and development program focused on next-generation Alpha-emitting isotopes for targeted alpha therapy. This strategic initiative aims to develop novel radiopharmaceuticals for hard-to-treat cancers, leveraging GE's expertise in both medical imaging and nuclear medicine.

Key Players Analysis

Key players like Lantheus Medical Imaging and Cardinal Health dominate the global medical radioactive isotopes market, focusing on production and distribution for diagnostic and therapeutic applications. Thermo Fisher Scientific and GE Healthcare provide essential imaging equipment and radiopharmaceuticals. Strategic initiatives include NorthStar Medical Radioisotopes advancing non uranium production methods and Cisbio International innovating detection technologies, all driving market growth through expanded access and novel radioisotope development.

List of Key Companies:

  1. Cisbio International
  2. Thermo Fisher Scientific
  3. Belgian Nuclear Research Centre
  4. Cardinal Health
  5. Lantheus Medical Imaging
  6. Elekta
  7. Tractebel
  8. Nuclear Medicine Partners
  9. NorthStar Medical Radioisotopes
  10. General Electric
  11. Honeywell
  12. Ryder System
  13. Isotope Technologies Garching
  14. Babcock & Wilcox
  15. Siemens Healthineers

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 6.8 Billion
Forecast Value (2035)USD 13.5 Billion
CAGR (2026-2035)7.6%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Application:
    • •Therapeutic
    • •Diagnostic Imaging
    • •Research
  • By Isotope Type:
    • •Technetium-99m
    • •Iodine-131
    • •Cobalt-60
    • •Iridium-192
  • By End Use:
    • •Hospitals
    • •Diagnostic Laboratories
    • •Research Institutes
    • •Cancer Treatment Centers
  • By Source:
    • •Natural
    • •Artificial
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Medical Radioactive Isotopes Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.1.1. Therapeutic
5.1.2. Diagnostic Imaging
5.1.3. Research
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Isotope Type
5.2.1. Technetium-99m
5.2.2. Iodine-131
5.2.3. Cobalt-60
5.2.4. Iridium-192
5.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
5.3.1. Hospitals
5.3.2. Diagnostic Laboratories
5.3.3. Research Institutes
5.3.4. Cancer Treatment Centers
5.4. Market Analysis, Insights and Forecast, 2020-2035, By Source
5.4.1. Natural
5.4.2. Artificial
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Medical Radioactive Isotopes Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.1.1. Therapeutic
6.1.2. Diagnostic Imaging
6.1.3. Research
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Isotope Type
6.2.1. Technetium-99m
6.2.2. Iodine-131
6.2.3. Cobalt-60
6.2.4. Iridium-192
6.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
6.3.1. Hospitals
6.3.2. Diagnostic Laboratories
6.3.3. Research Institutes
6.3.4. Cancer Treatment Centers
6.4. Market Analysis, Insights and Forecast, 2020-2035, By Source
6.4.1. Natural
6.4.2. Artificial
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Medical Radioactive Isotopes Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.1.1. Therapeutic
7.1.2. Diagnostic Imaging
7.1.3. Research
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Isotope Type
7.2.1. Technetium-99m
7.2.2. Iodine-131
7.2.3. Cobalt-60
7.2.4. Iridium-192
7.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Research Institutes
7.3.4. Cancer Treatment Centers
7.4. Market Analysis, Insights and Forecast, 2020-2035, By Source
7.4.1. Natural
7.4.2. Artificial
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Medical Radioactive Isotopes Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.1.1. Therapeutic
8.1.2. Diagnostic Imaging
8.1.3. Research
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Isotope Type
8.2.1. Technetium-99m
8.2.2. Iodine-131
8.2.3. Cobalt-60
8.2.4. Iridium-192
8.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Research Institutes
8.3.4. Cancer Treatment Centers
8.4. Market Analysis, Insights and Forecast, 2020-2035, By Source
8.4.1. Natural
8.4.2. Artificial
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Medical Radioactive Isotopes Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.1.1. Therapeutic
9.1.2. Diagnostic Imaging
9.1.3. Research
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Isotope Type
9.2.1. Technetium-99m
9.2.2. Iodine-131
9.2.3. Cobalt-60
9.2.4. Iridium-192
9.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Research Institutes
9.3.4. Cancer Treatment Centers
9.4. Market Analysis, Insights and Forecast, 2020-2035, By Source
9.4.1. Natural
9.4.2. Artificial
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Medical Radioactive Isotopes Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.1.1. Therapeutic
10.1.2. Diagnostic Imaging
10.1.3. Research
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Isotope Type
10.2.1. Technetium-99m
10.2.2. Iodine-131
10.2.3. Cobalt-60
10.2.4. Iridium-192
10.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
10.3.1. Hospitals
10.3.2. Diagnostic Laboratories
10.3.3. Research Institutes
10.3.4. Cancer Treatment Centers
10.4. Market Analysis, Insights and Forecast, 2020-2035, By Source
10.4.1. Natural
10.4.2. Artificial
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Cisbio International
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Thermo Fisher Scientific
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Belgian Nuclear Research Centre
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Cardinal Health
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Lantheus Medical Imaging
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Elekta
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Tractebel
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Nuclear Medicine Partners
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. NorthStar Medical Radioisotopes
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. General Electric
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Honeywell
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Ryder System
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. Isotope Technologies Garching
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Babcock & Wilcox
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. Siemens Healthineers
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 2: Global Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Isotope Type, 2020-2035

Table 3: Global Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 4: Global Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Source, 2020-2035

Table 5: Global Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 7: North America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Isotope Type, 2020-2035

Table 8: North America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 9: North America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Source, 2020-2035

Table 10: North America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 12: Europe Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Isotope Type, 2020-2035

Table 13: Europe Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 14: Europe Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Source, 2020-2035

Table 15: Europe Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 17: Asia Pacific Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Isotope Type, 2020-2035

Table 18: Asia Pacific Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 19: Asia Pacific Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Source, 2020-2035

Table 20: Asia Pacific Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 22: Latin America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Isotope Type, 2020-2035

Table 23: Latin America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 24: Latin America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Source, 2020-2035

Table 25: Latin America Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 27: Middle East & Africa Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Isotope Type, 2020-2035

Table 28: Middle East & Africa Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 29: Middle East & Africa Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Source, 2020-2035

Table 30: Middle East & Africa Medical Radioactive Isotopes Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Chemicals Market Research

Explore comprehensive market research reports covering all aspects of the Chemicals industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;